A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
City of Hope Medical Center
University College, London
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
Children's Oncology Group
Children's Oncology Group
SWOG Cancer Research Network
OHSU Knight Cancer Institute
Gruppo Italiano Malattie EMatologiche dell'Adulto
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
BTG International Inc.
University Hospital Schleswig-Holstein
South Plains Oncology Consortium
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Alliance for Clinical Trials in Oncology
Takeda
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Children's Oncology Group
University of Texas Southwestern Medical Center
Prince of Wales Hospital, Shatin, Hong Kong
Masonic Cancer Center, University of Minnesota
Regimmune Corporation
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
Dutch Childhood Oncology Group
Therapeutic Advances in Childhood Leukemia Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Nanfang Hospital, Southern Medical University